Loading...
XSHE
000650
Market cap1.18bUSD
Dec 05, Last price  
6.05CNY
1D
0.50%
1Q
-6.20%
Jan 2017
-14.18%
Name

Renhe Pharmacy Co.

Chart & Performance

D1W1MN
XSHE:000650 chart
P/E
17.29
P/S
2.04
EPS
0.35
Div Yield, %
3.31%
Shrs. gr., 5y
2.26%
Rev. gr., 5y
-2.31%
Revenues
4.07b
-19.02%
267,138,38924,943,408778,664,871876,460,543982,736,8271,366,781,2962,207,708,5392,087,519,1611,799,375,8362,253,212,4352,523,842,6633,567,078,2603,843,771,3514,403,423,4744,581,171,5794,106,104,1874,935,755,2085,153,215,0695,032,146,1234,074,892,927
Net income
482m
-15.05%
0130,301,62139,170,35170,161,003165,493,385219,530,952300,353,372255,461,059194,182,835300,907,595391,303,600372,380,254380,226,696506,464,000537,826,647580,180,490665,024,502574,430,143567,257,498481,911,678
CFO
557m
-3.50%
0235,279,50335,397,39762,141,462200,579,110130,072,804166,926,090183,966,860213,355,358365,274,345434,765,147522,083,291497,855,600569,454,435693,970,679871,131,642777,717,5301,269,978,522577,442,920557,258,083
Dividend
Jul 08, 20240.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Renhe Pharmacy Co., Ltd. produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, topical lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in 1996 and is headquartered in Nanchang, China.
IPO date
Dec 10, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT